These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 32344161)
1. Anti-neurofilament antibodies and neurodegeneration: Markers and generators. Zmira O; Halpern AI; Drori T J Neuroimmunol; 2020 Jul; 344():577248. PubMed ID: 32344161 [TBL] [Abstract][Full Text] [Related]
2. Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis. Gnanapavan S; Grant D; Pryce G; Jackson S; Baker D; Giovannoni G Autoimmunity; 2012 Jun; 45(4):298-303. PubMed ID: 22276904 [TBL] [Abstract][Full Text] [Related]
3. Neurofilament Proteins as Prognostic Biomarkers in Neurological Disorders. Lee Y; Lee BH; Yip W; Chou P; Yip BS Curr Pharm Des; 2020; 25(43):4560-4569. PubMed ID: 31820696 [TBL] [Abstract][Full Text] [Related]
4. Specificity of human anti-neurofilament autoantibodies. Braxton DB; Williams M; Kamali D; Chin S; Liem R; Latov N J Neuroimmunol; 1989 Feb; 21(2-3):193-203. PubMed ID: 2492307 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of antibodies to neurofilament polypeptides in patients with rheumatoid arthritis complicated by peripheral neuropathy. Salih AM; Nixon NB; Dawes PT; Mattey DL Clin Exp Rheumatol; 1998; 16(6):689-94. PubMed ID: 9844761 [TBL] [Abstract][Full Text] [Related]
6. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535 [TBL] [Abstract][Full Text] [Related]
7. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Brureau A; Blanchard-Bregeon V; Pech C; Hamon S; Chaillou P; Guillemot JC; Barneoud P; Bertrand P; Pradier L; Rooney T; Schussler N Neurobiol Dis; 2017 Aug; 104():73-84. PubMed ID: 28392472 [TBL] [Abstract][Full Text] [Related]
8. Neurofilaments as biomarkers in neurological disorders - towards clinical application. Khalil M; Teunissen CE; Lehmann S; Otto M; Piehl F; Ziemssen T; Bittner S; Sormani MP; Gattringer T; Abu-Rumeileh S; Thebault S; Abdelhak A; Green A; Benkert P; Kappos L; Comabella M; Tumani H; Freedman MS; Petzold A; Blennow K; Zetterberg H; Leppert D; Kuhle J Nat Rev Neurol; 2024 May; 20(5):269-287. PubMed ID: 38609644 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature. Gagliardi D; Meneri M; Saccomanno D; Bresolin N; Comi GP; Corti S Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450699 [TBL] [Abstract][Full Text] [Related]
10. Neurofilament antibodies in systemic lupus erythematosus. Kurki P; Helve T; Dahl D; Virtanen I J Rheumatol; 1986 Feb; 13(1):69-73. PubMed ID: 3517324 [TBL] [Abstract][Full Text] [Related]
11. Phosphorylated neurofilament heavy chain: a potential diagnostic biomarker in amyotrophic lateral sclerosis. Heckler I; Venkataraman I J Neurophysiol; 2022 Mar; 127(3):737-745. PubMed ID: 35138963 [TBL] [Abstract][Full Text] [Related]
12. Neurofilaments in health and disease. Julien JP; Mushynski WE Prog Nucleic Acid Res Mol Biol; 1998; 61():1-23. PubMed ID: 9752717 [TBL] [Abstract][Full Text] [Related]
13. [Evaluation of serum neurofilament light chains levels for diagnosis, treatment monitoring and prognosis in multiple sclerosis]. Alifirova VM; Kamenskikh EM; Koroleva ES Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):7-13. PubMed ID: 31934983 [TBL] [Abstract][Full Text] [Related]
15. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Kovacs GG; Andreasson U; Liman V; Regelsberger G; Lutz MI; Danics K; Keller E; Zetterberg H; Blennow K Eur J Neurol; 2017 Nov; 24(11):1326-e77. PubMed ID: 28816001 [TBL] [Abstract][Full Text] [Related]
16. Neurofilament light as an immune target for pathogenic antibodies. Puentes F; van der Star BJ; Boomkamp SD; Kipp M; Boon L; Bosca I; Raffel J; Gnanapavan S; van der Valk P; Stephenson J; Barnett SC; Baker D; Amor S Immunology; 2017 Dec; 152(4):580-588. PubMed ID: 28718500 [TBL] [Abstract][Full Text] [Related]
17. Neurofilament light chain in the assessment of patients with multiple sclerosis. Domingues RB; Fernandes GBP; Leite FBVM; Senne C Arq Neuropsiquiatr; 2019 Jul; 77(6):436-441. PubMed ID: 31314847 [TBL] [Abstract][Full Text] [Related]
18. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376 [TBL] [Abstract][Full Text] [Related]
19. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Ehling R; Lutterotti A; Wanschitz J; Khalil M; Gneiss C; Deisenhammer F; Reindl M; Berger T Mult Scler; 2004 Dec; 10(6):601-6. PubMed ID: 15584481 [TBL] [Abstract][Full Text] [Related]
20. Molecular architecture of the neurofilament. II. Reassembly process of neurofilament L protein in vitro. Hisanaga S; Hirokawa N J Mol Biol; 1990 Feb; 211(4):871-82. PubMed ID: 2313699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]